RemeGen cools on DR5
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
